Related Experiment Videos

T cell-tumor cell: a fatal interaction?

D B Chappell1, N P Restifo

  • 1The Howard Hughes Medical Institute-National Institutes of Health Research Scholars Program, Bethesda MD 20814, USA.

Insights

The Fas/FasL system regulates cell death and survival. Tumor cells expressing Fas Ligand (FasL) may indicate uncontrolled proliferation and T cell deletion, establishing immune privilege.

Area of Science:

  • Immunology
  • Cell Biology
  • Cancer Biology

Background:

  • Fas (Apo-1/CD95) initiates apoptosis via caspase cascades.
  • The Fas/FasL system is known to dampen immune responses by deleting activated T cells.
  • Tumor cells are proposed to express FasL to evade immune surveillance.

Purpose of the Study:

  • To review the role of Fas/FasL interactions in modulating antitumor responses.
  • To critically evaluate evidence for FasL expression by tumor cells.
  • To explore alternative explanations for observed FasL phenomena in vitro and in vivo.

Main Methods:

  • Literature review of published data.
  • Analysis of laboratory-generated data.
  • Critical examination of in vitro and in vivo experimental findings.

Main Results:

  • The Fas/FasL system acts as a general autocrine mechanism for regulating cell survival and expansion.
  • Tumor cell FasL expression is not consistently proven and may have alternative explanations.
  • Observed FasL expression in tumors suggests a disruption in proliferation control.

Conclusions:

  • The Fas/FasL system is a fundamental regulator of cell fate.
  • Tumor cell FasL expression is linked to dysregulated proliferation and immune evasion.
  • Immune privilege in tumors can arise from activation-induced cell death of T cells.

Related Concept Videos